Form 4: Myriad Genetics Chief People Officer Reports Stock Transaction
SEC Form 4 Filing
Shereen Solaiman, Chief People Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 1, 2025, Shereen Solaiman, Chief People Officer of Myriad Genetics, reported a transaction involving Myriad Genetics common stock.
- The transaction involved the withholding of 1,912 shares of common stock to satisfy tax withholding obligations related to the vesting of restricted stock units.
- The shares were withheld at a price of $10.73 per share, based on the closing price of Myriad common stock on February 28, 2025.
- Following the transaction, Solaiman directly owns 53,878 shares of Myriad Genetics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by a company officer, and does not contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Key Dates
| Date | Description |
|---|---|
| February 28, 2025 | Date used to determine the closing price of Myriad common stock for tax withholding. |
| March 01, 2025 | Date of the stock transaction (share withholding). |
| March 03, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.